The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Abstract
IL-6 plays a pivotal role in immune responses and certain oncologic conditions. The intense investigation of its biological activity and function led to the discovery of two different IL-6-driven signalling pathways. Binding to the membrane-bound IL-6 receptor (mIL-6R, CD126) causes the recruitment of two gp130 co-receptor molecules (CD130) and the activation of intracellular signalling cascades via gp130. Although this classical pathway is mainly limited to hepatocytes, neutrophils, monocytes/macrophages and certain other leukocyte populations, which express IL-6R on their surface, an alternative mechanism has also been described. Proteolytic cleavage of the mIL-6R protein or translation from alternatively spliced mRNA leads to the generation of a soluble form of the IL-6R (sIL-6R), which is likewise able to bind to IL-6. The resulting IL-6/sIL-6R complex is also capable of binding to gp130 and inducing intracellular signalling. Through this so-called 'trans-signalling' mechanism, IL-6 is able to stimulate cells that lack an endogenous mIL-6R. High levels of IL-6 and sIL-6R have been reported in several chronic inflammatory and autoimmune diseases as well as in cancer. Preclinical animal disease models have provided strong evidence that specific blockade of IL-6-regulated signalling pathways represents a promising approach for the therapy of these diseases. An optimised variant of the recently described fusion protein sgp30Fc is now heading towards its clinical evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic Cells
Pasare, C., & Medzhitov, R. (2003) · Science · doi:10.1126/science.1078231 · Cited by 1,997
Manolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Gauldie, J., Richards, C., Harnish, D., Lansdorp, P., & Baumann, H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7251 · Cited by 1,635
Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X. F., & Achong, M. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1368 · Cited by 1,498
gp 130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES
Taga, T., & Kishimoto, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.797 · Cited by 1,461
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,442
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Interleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationPowrie, F., Leach, M. W., Mauze, S., Menon, S., Barcomb Caddle, L., & Coffman, R. L. (1994) · Immunity · doi:10.1016/1074-7613(94)90045-0 · Cited by 1,146 · cited 1×
“Severe combined immunodeficient mice transferred with 1 x 106 CD62L+CD45RbhighCD4+ T cells [99] were given 500 μg of sgp130Fc at day 0 (= 10 weeks after adoptive transfer), day 9 and day 16.”
MethodRole of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,112
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S. R., Haugen, H. S., Maurer, M., Harder, B., Johnston, J., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,015
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928 · cited 1×
“This has been reported for many different diseases, for example inflammatory bowel diseases (IBD) [38-42], rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis [43-45], asthma and interstitial lung disease [46,47], osteoporosis [48,49], cachexia [50], sepsis [51,52], glomerulonephritis [53], multiple…”
BackgroundREINECKER, H.-C., STEFFEN, M., WITTHOEFT, T., PFLUEGER, I., SCHREIBER, S., MacDERMOTT, R. P., & RAEDLER, A. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb05997.x · Cited by 856
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Self-citationNishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., & Kishimoto, T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20303 · Cited by 788
Soluble receptors for cytokines and growth factors: generation and biological function
Rose-John, S., & Heinrich, P. C. (1994) · Biochemical Journal · doi:10.1042/bj3000281 · Cited by 775
Self-citationGardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R., & Vinh, D. C. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00545-0 · Cited by 752
TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726
Self-citationWSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27
Pflanz, S., Hibbert, L., Mattson, J., Rosales, R., Vaisberg, E., Bazan, J. F., Phillips, J. H., McClanahan, T. K., de Waal Malefyt, R., & Kastelein, R. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2225 · Cited by 695
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
Strassmann, G., Fong, M., Kenney, J. S., & Jacob, C. O. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115767 · Cited by 658
Hexameric Structure and Assembly of the Interleukin-6/IL-6 α-Receptor/gp130 Complex
Boulanger, M. J., Chow, D.-C., Brevnova, E. E., & Garcia, K. C. (2003) · Science · doi:10.1126/science.1083901 · Cited by 642
Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Self-citationHaemopoietic receptors and helical cytokines
Bazan, J. F. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90139-z · Cited by 638
Interleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604 · cited 1×
“IL-6-deficient mice have been shown to be resistant to the induction of experimental autoimmune conditions [107-110].”
BackgroundKotake, S., Sato, K., Kim, K. J., Takahashi, N., Udagawa, N., Nakamura, I., Yamaguchi, A., Kishimoto, T., Suda, T., & Kashiwazaki, S. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110113 · Cited by 545
Transcriptional profiling identifies Id2 function in dendritic cell development
Hacker, C., Kirsch, R. D., Ju, X.-S., Hieronymus, T., Gust, T. C., Kuhl, C., Jorgas, T., Kurz, S. M., Rose-John, S., Yokota, Y., et al. (2003) · Nature Immunology · doi:10.1038/ni903 · Cited by 544
Self-citationChoy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526 · cited 1×
“2 Rheumatoid arthritis Recent results from Phase I and Phase II clinical trials with an anti-IL-6R antibody (MRA, tocilizumab) in patients with rheumatoid arthritis revealed improved disease activity [103].”
BackgroundPoli, G., Bressler, P., Kinter, A., Duh, E., Timmer, W. C., Rabson, A., Justement, J. S., Stanley, S., & Fauci, A. S. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.1.151 · Cited by 512
The soluble interleukin‐6 receptor is generated by shedding
Mülberg, J., Schooltink, H., Stoyan, T., Günther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P. C., & Rose‐John, S. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230226 · Cited by 506
Self-citationTrikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506
Involvement of IL-6 in mesangial proliferative glomerulonephritis.
Horii, Y., Muraguchi, A., Iwano, M., Matsuda, T., Hirayama, T., Yamada, H., Fujii, Y., Dohi, K., Ishikawa, H., Ohmoto, Y., et al. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.12.3949 · Cited by 408
Interleukin 6 plays a key role in the development of antigen-induced arthritis
Ohshima, S., Saeki, Y., Mima, T., Sasai, M., Nishioka, K., Nomura, S., Kopf, M., Katada, Y., Tanaka, T., Suemura, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8222 · Cited by 406 · cited 1×
“IL-6-deficient mice have been shown to be resistant to the induction of experimental autoimmune conditions [107-110].”
BackgroundComplex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins
Mackiewicz, A., Schooltink, H., Heinrich, P. C., & Rose-John, S. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.6.2021 · Cited by 370
Self-citationYokota, S., Miyamae, T., Imagawa, T., Iwata, N., Katakura, S., Mori, M., Woo, P., Nishimoto, N., Yoshizaki, K., & Kishimoto, T. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20944 · Cited by 370
Cytokine traps: multi-component, high-affinity blockers of cytokine action
Economides, A. N., Carpenter, L. R., Rudge, J. S., Wong, V., Koehler-Stec, E. M., Hartnett, C., Pyles, E. A., Xu, X., Daly, T. J., Young, M. R., et al. (2003) · Nature Medicine · doi:10.1038/nm811 · Cited by 359
Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G., Taga, T., & Kishimoto, T. (1993) · Blood · doi:10.1182/blood.v82.4.1120.1120 · Cited by 343
Doganci, A., Eigenbrod, T., Krug, N., De Sanctis, G. T., Hausding, M., Erpenbeck, V. J., Haddad, E.-B., Schmitt, E., Bopp, T., Kallen, K.-J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22433 · Cited by 333
Self-citationSympathetic neurons can produce and respond to interleukin 6
März, P., Cheng, J.-G., Gadient, R. A., Patterson, P. H., Stoyan, T., Otten, U., & Rose-John, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3251 · Cited by 332
Self-citationHuman soluble IL-6 receptor: its detection and enhanced release by HIV infection
Honda, M., Yamamoto, S., Cheng, M., Yasukawa, K., Suzuki, H., Saito, T., Osugi, Y., Tokunaga, T., & Kishimoto, T. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.7.2175 · Cited by 331
Maintenance of Pluripotency in Human Embryonic Stem Cells Is STAT3 Independent
Humphrey, R. K., Beattie, G. M., Lopez, A. D., Bucay, N., King, C. C., Firpo, M. T., Rose‐John, S., & Hayek, A. (2004) · STEM CELLS · doi:10.1634/stemcells.22-4-522 · Cited by 319
Self-citationIsolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
Lust, J. A., Donovan, K. A., Kline, M. P., Greipp, P. R., Kyle, R. A., & Maihle, N. J. (1992) · Cytokine · doi:10.1016/1043-4666(92)90043-q · Cited by 316
Doganci, A., Eigenbrod, T., Krug, N., De Sanctis, G. T., Hausding, M., Erpenbeck, V. J., Haddad, E.-B., Schmitt, E., Bopp, T., Kallen, K.-J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522433 · Cited by 304
Self-citationEvidence for continuous stimulation of interleukin-6 production in Crohn's disease
Gross, V., Andus, T., Caesar, I., Roth, M., & Schölmerich, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90098-j · Cited by 293
Interleukin-6 and its receptor: from bench to bedside
Scheller, J., & Rose-John, S. (2006) · Medical Microbiology and Immunology · doi:10.1007/s00430-006-0019-9 · Cited by 292
Self-citationMcLoughlin, R. M., Witowski, J., Robson, R. L., Wilkinson, T. S., Hurst, S. M., Williams, A. S., Williams, J. D., Rose-John, S., Jones, S. A., & Topley, N. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17129 · Cited by 281 · cited 1×
“Recently, it has been shown that hematopoietic progenitor cells [17-20], T cells [21-23], embryonic stem cells [24,25], many neural cells [26-28], smooth muscle cells [29], mesothelial cells [30,31], endothelial cells [32] and keratinocytes [33] are sensitised through sIL-6R and thereby become responsive to IL-6.”
BackgroundSelf-citationInterleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis
Peters, M., Müller, A. M., & Rose-John, S. (1998) · Blood · doi:10.1182/blood.v92.10.3495 · Cited by 276
Self-citationTreatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.
Wendling, D., Racadot, E., & Wijdenes, J. (1993) · PubMed · Cited by 274
The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site.
Müllberg, J., Oberthür, W., Lottspeich, F., Mehl, E., Dittrich, E., Graeve, L., Heinrich, P. C., & Rose-John, S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.10.4958 · Cited by 269
Self-citationNowell, M. A., Richards, P. J., Horiuchi, S., Yamamoto, N., Rose-John, S., Topley, N., Williams, A. S., & Jones, S. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3202 · Cited by 268
Self-citationIL-6 Signaling Promotes Tumor Growth in Colorectal Cancer
Becker, C., Fantini, M. C., Wirtz, S., Nikolaev, A., Lehr, H. A., Galle, P. R., John, R., & Neurath, M. F. (2005) · Cell Cycle · doi:10.4161/cc.4.2.1413 · Cited by 255
CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex
Elson, G. C. A., Lelièvre, E., Guillet, C., Chevalier, S., Plun-Favreau, H., Froger, J., Suard, I., de Coignac, A. B., Delneste, Y., Bonnefoy, J.-Y., et al. (2000) · Nature Neuroscience · doi:10.1038/78765 · Cited by 252
Circulating interleukin-6 levels in patients with bronchial asthma.
Yokoyama, A., Kohno, N., Fujino, S., Hamada, H., Inoue, Y., Fujioka, S., Ishida, S., & Hiwada, K. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.5.7735584 · Cited by 248
Localization of estrogen receptor ?-immunoreactivity in astrocytes of the adult rat brain
Azcoitia, Í., Sierra, A., & García‐Segura, L. M. (1999) · Glia · doi:10.1002/(sici)1098-1136(199905)26:3<191::aid-glia1>3.0.co;2-# · Cited by 218
The Interleukin-6 Cytokine System Regulates Epidermal Permeability Barrier Homeostasis
Wang, X.-P., Schunck, M., Kallen, K., Neumann, C., Trautwein, C., Rose‐John, S., & Proksch, E. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22736.x · Cited by 205
Self-citationThe role of transsignalling via the agonistic soluble IL-6 receptor in human diseases
Kallen, K.-J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00325-7 · Cited by 205
Modur, V, Li, Y., Zimmerman, G. A., Prescott, S. M., & McIntyre, T. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119821 · Cited by 204
Inhibition of IL-6 for the treatment of inflammatory diseases
NISHIMOTO, N. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.005 · Cited by 200
Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model
Barton, B. E., & Jackson, J. V. (1993) · Infection and Immunity · doi:10.1128/iai.61.4.1496-1499.1993 · Cited by 200
Horiuchi, S., Koyanagiu, Y., Zhouu, Y., Miyamotou, H., Tanakau, Y., Waki, M., Matsumoto, A., Yamamotou, M., & Yamamotof, N. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240837 · Cited by 197
Anti-TNF-?-induced systemic lupus syndrome
Debandt, M., Vittecoq, O., Descamps, V., Lo�t, X. L., & Meyer, O. (2003) · Clinical Rheumatology · doi:10.1007/s10067-002-0654-5 · Cited by 189
Prevalence of Hypophosphatemia in Sepsis and Infection: The Role of Cytokines
Barak, V., Schwartz, A., Kalickman, I., Nisman, B., Gurman, G., & Shoenfeld, Y. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00275-1 · Cited by 187
Mitsuyama, K., Toyonaga, A., Sasaki, E., Ishida, O., Ikeda, H., Tsuruta, O., Harada, K., Tateishi, H., Nishiyama, T., & Tanikawa, K. (1995) · Gut · doi:10.1136/gut.36.1.45 · Cited by 186
Klouche, M., Bhakdi, S., Hemmes, M., & Rose-John, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4583 · Cited by 178
Self-citationPeters, M., Schirmacher, P., Goldschmitt, J., Odenthal, M., Peschel, C., Fattori, E., Ciliberto, G., Dienes, H.-P., Büschenfelde, K.-H. M. Z., & Rose-John, S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.755 · Cited by 170
Self-citationSoluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses
Müller-Newen, G., Küster, A., Hemmann, U., Keul, R., Horsten, U., Martens, A., Graeve, L., Wijdenes, J., & Heinrich, P. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6347 · Cited by 162
Robak, T., Gladalska, A., Stepień, H., & Robak, E. (1998) · Mediators of Inflammation · doi:10.1080/09629359890875 · Cited by 161
Gijbels, K., Brocke, S., Abrams, J. S., & Steinman, L. (1995) · Molecular Medicine · doi:10.1007/bf03401894 · Cited by 156
Anti-cytokine therapeutics and infections
Dinarello, C. A. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00196-8 · Cited by 148
Klouche, M., Rose‐John, S., Schmiedt, W., & Bhakdi, S. (2000) · Circulation · doi:10.1161/01.cir.101.15.1799 · Cited by 146
Self-citationInterleukin-6 and its receptor are expressed in human intestinal epithelial cells
Shirota, K., Leduy, L., Yuan, S., & Jothy, S. (1989) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02890085 · Cited by 146
Pathological Role of IL-6 in the Experimental Allergic Bronchial Asthma in Mice
Doganci, A., Sauer, K., Karwot, R., & Finotto, S. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:257 · Cited by 142
Interleukin-6: a new therapeutic target
Smolen, J., & Maini, R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1969 · Cited by 131
STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice
Mitsuyama, K., Matsumoto, S., Rose‐John, S., Suzuki, A., Hara, T., Tomiyasu, N., Handa, K., Tsuruta, O., Funabashi, H., Scheller, J., et al. (2006) · Gut · doi:10.1136/gut.2005.079343 · Cited by 130
Self-citationNeural activities of IL‐6‐type cytokines often depend on soluble cytokine receptors
März, P., Otten, U., & Rose‐John, S. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00755.x · Cited by 127
Self-citationInterleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease
Hosokawa, T., Kusugami, K., Ina, K., Ando, T., Shinoda, M., Imada, A., Ohsuga, M., Sakai, T., Matsuura, T., Ito, K., et al. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01989.x · Cited by 123
Signaling mechanisms through cytokine receptors that share signal transducing receptor components
Taga, T., & Kishimoto, T. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80024-7 · Cited by 122
Differential shedding of the two subunits of the interleukin‐6 receptor
Müllberg, J., Dittrich, E., Graeve, L., Gerhartz, C., Yasukawa, K., Taga, T., Kishimoto, T., Heinrich, P. C., & Rose‐John, S. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80507-q · Cited by 118
Self-citationSilacci, P., Dayer, J., Desgeorges, A., Peter, R. E., Manueddu, C., & Guerne, P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13625 · Cited by 118
Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor
Müllberg, J., Schooltink, H., Stoyan, T., Heinrich, P. C., & Rose‐John, S. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)92272-y · Cited by 118
Self-citationIL-6 Type Cytokine Receptor Complexes: Hexamer, Tetramer or Both?
Grötzinger, J., Kernebeck, T., Kallen, K., & Rose‐John, S. (1999) · Biological Chemistry · doi:10.1515/bc.1999.100 · Cited by 111
Self-citationReceptor blockade with monoclomal antibodies as anti-cancer therapy
Baselga, J. M., & Mendelsohn, J. M. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90036-1 · Cited by 107
Colonic Mucosal Interleukin-6 in Inflammatory Bowel Disease
Mitsuyama, K., Sasaki, E., Toyonaga, A., Ikeda, H., Tsuruta, O., Irie, A., Arima, N., Oriishi, T., Harada, K., Fujisaki, K., et al. (2009) · Digestion · doi:10.1159/000200747 · Cited by 103
Boughton-Smith, N. K., Wallace, J. L., Morris, G. P., & Whittle, B. J. R. (1988) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1988.tb11500.x · Cited by 102
Padberg, F., Feneberg, W. W., Schmidt, S., Schwarz, M., Körschenhausen, D. A., Greenberg, B. D., Nolde, T., Müller, N., Trapmann, H., König, N., et al. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00120-4 · Cited by 101
Keul, R., Heinrich, P. C., Müller-Newen, G., Muller, K., & Woo, P. (1998) · Cytokine · doi:10.1006/cyto.1997.0343 · Cited by 98
The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody
Mihara, M., Nishimoto, N., & Ohsugi, Y. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.5.683 · Cited by 98
Nishimura, R., Moriyama, K., Yasukawa, K., Mundy, G. R., & Yoneda, T. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.5.777 · Cited by 90
Dynamics of the gp130 cytokine complex: A model for assembly on the cellular membrane
Schroers, A., Hecht, O., Kallen, K., Pachta, M., Rose‐John, S., & Grötzinger, J. (2005) · Protein Science · doi:10.1110/ps.041117105 · Cited by 81
Self-citationDiamant, M., Rieneck, K., Mechti, N., Zhang, X., Svenson, M., Bendtzen, K., & Klein, B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00750-3 · Cited by 79
Molecular mechanisms of cytokine receptor activation
Grötzinger, J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00316-6 · Cited by 78
Self-citationNo inhibition of IL-27 signaling by soluble gp130
Scheller, J., Schuster, B., Hölscher, C., Yoshimoto, T., & Rose‐John, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.098 · Cited by 74
Self-citationMärz, P., Heese, K., Höck, C., Golombowski, S., Müller-Spahn, F., Rose‐John, S., & Otten, U. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00886-0 · Cited by 74
Self-citationWhy does tumor necrosis factor targeted therapy reactivate tuberculosis?
Ehlers, S. (2005) · PubMed · Cited by 73
Rakemann, T., Niehof, M., Kubicka, S., Fischer, M., Manns, M. P., Rose‐John, S., & Trautwein, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1257 · Cited by 66
Self-citationRole of interleukin 6 in the growth of myelomaderived cell lines
Barut, B., Zon, L. I., Cochran, M. K., Paul, S. R., Chauhan, D., Mohrbacher, A., Fingeroth, J. D., & Anderson, K. C. (1992) · Leukemia Research · doi:10.1016/0145-2126(92)90073-g · Cited by 66
Yasukawa, K., Futatsugi, K., Saito, T., Yawata, H., Narazaki, M., Suzuki, H., Taga, T., & Kishimoto, T. (1992) · Immunology Letters · doi:10.1016/0165-2478(92)90138-e · Cited by 64
Suzuki, Y., Yang, Q., Conley, F. K., Abrams, J. S., & Remington, J. S. (1994) · Infection and Immunity · doi:10.1128/iai.62.7.2773-2778.1994 · Cited by 62
Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease
Hampel, H. J., Sunderland, T., Kötter, H. U., Schneider, C., Teipel, S. J., Padberg, F., Dukoff, R. A., Levy, J., & Möller, H. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01355-3 · Cited by 57
Mini ReviewNew IL-6 (gp130) Family Cytokine Members, CLC/NNT1/BSF3 and IL-27
Murakami, M., Kamimura, D., & Hirano, T. (2004) · Growth Factors · doi:10.1080/08977190410001715181 · Cited by 52
Pflanz, S., Kurth, I., Grötzinger, J., Heinrich, P. C., & Müller‐Newen, G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7042 · Cited by 48
Self-citationGP130 stimulation and the maintenance of stem cells
Rose‐John, S. (2002) · Trends in biotechnology · doi:10.1016/s0167-7799(02)02056-5 · Cited by 47
Self-citationPallua, N., Low, J. F. A., & von Heimburg, D. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000065725.80882.bd · Cited by 42
The function of the soluble IL-6 receptor in vivo
Peters, M., Büschenfelde, K. M. Z., & Rose‐John, S. (1996) · Immunology Letters · doi:10.1016/s0165-2478(96)02669-7 · Cited by 40
Self-citationMontero‐Julian, F. A., Brailly, H., Sautès‐Fridman, C., Joyeux, I., Dorval, T., Mosseri, V., Yasukawa, K., Wijdenes, J., Adler, A., Gorin, I., et al. (1997) · PubMed · Cited by 40
Novel therapy for Crohn’s disease targeting IL-6 signalling
Ito, H. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.4.287 · Cited by 36
HORIUCHI, AMPOFO, Koyanagi, Yamashita, Waki, MATSUMOTO, YAMAMOTO, & YAMAMOTO (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00622.x · Cited by 34
Yokoyama, A., Kohno, N., Hirasawa, Y., KONDO, K., Abe, M., Inoue, Y., Fujioka, S., Fujino, S., ISHIDA, S., & Hiwada, K. (1995) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb03672.x · Cited by 32
Campard, D., Vasse, M., Rose‐John, S., Poyer, F., LAMACZ, M., & Vannier, J. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0173 · Cited by 28
Self-citationIL6 signalling through IL6 receptor and receptor-associated signal transducer, gp130
Taga, T. (1992) · Research in Immunology · doi:10.1016/0923-2494(92)80013-b · Cited by 28
Symmons, D. P. M., & Silman, A. J. (2006) · Lupus · doi:10.1191/0961203306lu2278rr · Cited by 28
Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP
Metz, S., Wiesinger, M., Vogt, M., Lauks, H., Schmalzing, G., Heinrich, P. C., & Müller‐Newen, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606885200 · Cited by 27
Molecular biology and immunology of interleukin-6.
Hirano, T., & Kishimoto, T. (1992) · Research in Immunology · doi:10.1016/0923-2494(92)80010-i · Cited by 26
Hodgkin and Reed-Sternberg Cells Express Interleukin 6 and Interleukin 6 Receptors
Tesch, H., Jüjcler, M., Klein, S. C., Abts, H. F., Güjnther, A., Krueger, G. R. F., & Diehl, V. (1992) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199209049781 · Cited by 22
Scheller, J., Kovaleva, M., Rabe, B., Eichler, J., Kallen, K., & Rose-John, S. (2004) · JIM - Journal of Immunological Methods · doi:10.1016/j.jim.2004.05.002 · Cited by 7
Self-citation
Cited by
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Self-citationMuscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
Pedersen, B. K., & Febbraio, M. A. (2008) · Physiological Reviews · doi:10.1152/physrev.90100.2007 · Cited by 2,388
Interleukin-6, a Major Cytokine in the Central Nervous System
Erta, M., Quintana, A., & Hidalgo, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4679 · Cited by 1,087
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
“These experiments allowed to decide whether the gp130 driven disease model was based on IL-6 classic signaling or IL-6 trans-signaling [54, 55].”
BackgroundMethodSelf-citationThe role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Metadata
- Authors
- Rose-John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2007-04-27
- Volume
- 11
- Issue
- 5
- Pages
- 613-624
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2018498519
- Cited by
- 360
- References
- 116
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.